|
ISPOR 10th ANNUAL INTERNATIONAL
MEETING
May 15-18,
2005, Marriott
Wardman Park Hotel, Washington, DC
“A DECADE AND
COUNTING: ARE WE IMPROVING HEALTH CARE DECISIONS?” |
|
|
|
8:00AM-8:30AM |
WELCOME & INTRODUCTION
|
|
Salon 2 |
J. Jaime Caro MD,
Scientific Director, Caro Research, Concord, MA, USA and ISPOR Program
Committee Chair
|
|
|
Presidential Address
Lieven Annemans PhD, MSc, Mman,
ISPOR 2004-2005 President, Director, HEDM and Professor of Health
Economics, University of Ghent, Meise, Belgium |
 |
ISPOR 10 YEARS – “Past,
Present and Future”
Marilyn Dix Smith PhD,
Founding Executive Director, ISPOR Lawrenceville NJ, USA |
|
8:30AM-9:45AM |
FIRST PLENARY SESSION |
Salon 2 |
Current Dilemmas in
Translating Research to Practice
Moderator:
Marilyn Dix
Smith RPh, PhD,
Executive Director, ISPOR, Lawrenceville, NJ, USA
This
plenary session will address a major deficiency in today's
practice of health economics.
Determinants of Health Economic Decisions in Actual Practice: The
Role of Behavioral Economics
Speaker: Daniel Kahneman PhD,
Eugene Higgins Professor of Psychology; Professor of Psychology
and Public Affairs Woodrow Wilson School, Princeton University,
Princeton, Bank of Sweden Prize in Economic
Sciences in Memory of Alfred Nobel, 2002
|
|
9:45AM-10:15AM |
EXHIBITS & CONTRIBUTED POSTER
PRESENTATIONS VIEWING - SESSION I
|
Exhibit Hall C
|
|
|
10:15AM-11:15AM |
CONTRIBUTED PODIUM PRESENTATIONS –
SESSION I
|
| Virginia AB |
Health Care Policy Studies I
HP1 MEDICAID DRUG SPENDING AFTER THE MEDICARE MODERNIZATION ACT: WHAT WILL BE LEFT?
Boulanger L, Brown J, Menzin J, Boston Health Economics, Inc, Waltham, MA, USA
HP2 EFFECTS OF PATIENTS' BELIEFS ABOUT MEDICATIONS ON NON-ADHERENCE TO CHRONIC
MEDICATIONS
Phatak HM, Thomas III J, Purdue University, West Lafayette, IN, USA
HP3 WHO WILL REQUEST A SWITCH TO NEW TREATMENT AS A RESULT OF DIRECT-TOCONSUMER
ADVERTISING?
Chen HD, Carroll N, Virginia Commonwealth University, Richmond, VA, USA
HP4 POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING FOR ELDERLY AMBULATORY
PATIENTS IN REGIONE EMILIA ROMAGNA, ITALY
Maio V, Yuen EJ, Novielli KD, Rabinowitz C, Louis DZ, Jefferson Medical College, Philadelphia, PA, USA
|
| Delaware AB |
Cancer
CN1 COST-EFFECTIVENESS OF ONCE WEEKLY EPOETIN ALFA AND DARBEPOETIN ALFA IN TREATING
CHEMOTHERAPY-INDUCED ANEMIA
Ben-Hamadi R1, Duh MS1, Aggarwal J1, Henckler A1, McKenzie S2, Fastenau J3, Piech CT3,
1Analysis Group Inc, Boston, MA, USA; 2Ortho Biotech Clinical Affairs LLC, Dallas, TX, USA;
3Ortho Biotech Clinical Affairs LLC, Bridgewater, NJ, USA
CN2 VALUE-FOR-MONEY OF PEMETREXED PLUS CISPLATIN VERSUS CISPLATIN ALONE IN THE
TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
Davey P1, Cordony A1, Rajan N2, Arora B2, Pavlakis N3, 1Medical Technology Assessment
Group Pty Ltd, Sydney, NSW, Australia; 2Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia;
3Royal North Shore Hospital, Sydney, NSW, Australia
CN3 ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCER THERAPIES
Nadler E1, Eckert B2, Neumann P2, 1Dana-Farber Cancer Institute, Boston, MA, USA; 2Harvard
University, Boston, MA, USA
CN4 EXPLICIT VALUATION OF PASS-THROUGH TECHNOLOGIES UNDER MEDICARE: IS IT FEASIBLE
OR DESIRABLE?
Mohr P, Paserchia L, Kornfield T, Centers for Medicare and Medicaid Services, Baltimore,
MD, USA |
| Salon 2 |
Methods & Concepts
MC1
WHY DO DIFFERENT MODELS COME TO
DIFFERENT CONCLUSIONS?: A STUDY OF EIGHT COST-EFFECTIVENESS ANALYSES
COMPARING COX-2 SPECIFIC INHIBITORS (COXIBS) AND NON STEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDS)
Risebrough NA1,
Drummond M2, Neumann P3, Lising A4,
Mittmann N5, Niculescu L6
1 HOPE Research Centre, Toronto, ON, Canada; 2
University of York, York, UK, 3 Harvard University,
Boston, MA, USA; 4 Dymaxium Inc, Toronto, ON, Canada;
5 University of Toronto, Toronto, ON, Canada; 6
Pfizer Inc, New York, NY, USA
MC2 EVALUATION OF MEDICATION ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Kim JW1, Livengood KB2, Nichol MB1, 1University of Southern California, School of Pharmacy,
Los Angeles, CA, USA; 2Pfizer Inc, New York, NY, USA
MC3 DOES METHOD OF CASE ASCERTAINMENT AFFECT ESTIMATES OF THE PREVALENCE AND
SEVERITY OF DEMENTIA IN MEDICARE NURSING HOME RESIDENTS?
Singhal PK, Stuart BC, University of Maryland at Baltimore, Baltimore, MD, USA
MC4 CHOOSING BETWEEN SF12/SF-36 PREFERENCE-BASED ALGORITHMS FOR COSTUTILITY
ANALYSIS
Pickard AS1, Wang ZX1, Lee TA2, Walton SM1, 1University of Illinois at Chicago, Chicago, IL,
USA; 2Hines VA Hospital, Hines, IL, USA |
| Maryland AB |
Musculoskeletal Diseases/Disorders
MS1 PARENTERAL PARECOXIB FOLLOWED BY ORAL VALDECOXIB AFTER MAJOR GENERAL
SURGERY REDUCES OPIOID CONSUMPTION AND OPIOID-RELATED SYMPTOMS
Katz JA1, Ferrante FM2, Neumann J3, Rowinski W4, Trzebicki J4, Kosieradzki M4, Brown MT5,
Boye M5,
1Northwestern University Medical Center, Chicago, IL, USA; 2UCLA, Los Angeles, CA, USA;
3Charles University Teaching Hospital of 2nd Medical School, Prague, Czech Republic;
4Medical University of Warsaw, Warsaw, Warsaw, Poland; 5Pfizer Inc, New York, NY, USA
MS2 CARDIOVASCULAR RISK FACTORS AT BASELINE IN USERS OF COXIBS COMPARED TO USERS
OF NSAIDS
De Jong RB, Breekveldt-Postma NS, Goettsch WG, Herings RM, PHARMO Institute, Utrecht,
Utrecht, Netherlands
MS3 ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN® TABLETS)
(CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS
PAIN OF THE HIP OR KNEE
Marshall DA1, Strauss ME2, Pericak D1, Buitendyk M1, Codding C3, Kim S2, Torrance G1,
1Innovus Research Inc, Burlington, ON, Canada; 2Purdue Pharma L.P, Stamford, CT, USA;
3Oklahoma Sports, Oklahoma City, OK, USA
MS4 THE COST-EFFECTIVENESS OF ADDING INFLIXIMAB TO USUAL THERAPY IN THE TREATMENT
OF PSORIATIC ARTHRITIS
Marra CA1, Maetzel A2, Farewell VT3, Rashidi AA1, Shi P1, Antoni C4, Wong JB5, Gladman DD6,
1University of British Columbia, Vancouver, BC, Canada; 2Toronto General Research Institute,
Toronto, ON, Canada; 3Institute of Public Health, Cambridge, UK; 4Schering-Plough Corporation, Kenilworth,
NJ, USA; 5Tufts-New England Medical Center, Boston, MA, USA; 6Toronto Western Research Institute,
oronto, ON, Canada |
|
11:30AM-12:30PM |
ISSUE PANEL – SESSION I (4 Issue Panels) |
Salon 2 |
Health Policy/Health Care Reimbursement/Coverage Issues
SHOULD MANUFACTURERS CONSULT WITH CMS STAFF ON THE PHASE III STUDY
DESIGN, AS CMS IS NOW REQUESTING?
Moderator:
Diane Simison PhD,
Executive Director, MEDTAP Center for Pricing and Reimbursement,
Arlington, VA USA
Panelists:
Steve Phurrough MD, MPA,
Director, Coverage Analysis Group, Centers for Medicare and
Medicaid Services, Baltimore, MD USA;
Beth A. Hahn PhD,
Managing Director, MEDTAP Center for Pricing and Reimbursement,
Arlington, VA USA
|
| Delaware AB |
AMCP FORMAT FOR FORMULARY SUBMISSIONS: PERSPECTIVES
ON DOSSIER PREPARATION AND REVIEW
Moderator: Shahnaz Khan, MPH,
Health Outcomes Communications Specialist, RTI Health Solutions,
Research Triangle Park, NC, USA
Panelists: Iris Tam PharmD,
Medical Communication Scientist, Genentech, Inc, South San
Francisco, CA, USA;
David Clark RPh, MBA,
Vice President Pharmacy Services, The Regence Group/RegenceRx,
Portland, OR, USA
|
| Virginia AB |
Issues on Use of Health Outcomes Research Information by
Decision-Makers
USE OF COST-EFFECTIVENESS ANALYSIS IN THE US MEDICARE PROGRAM AND
LESSONS FROM OTHER PAYORS
Moderator: Penny Mohr MA,
Health Economist,
Centers for Medicare and Medicaid Services, Baltimore,
MD, USA
Panelists:
Christopher McCabe PhD,
Senior Lecturer, The University of Sheffield, Sheffield, UK ;
Bernard Bloom PhD, Research Professor, University of Pennsylvania,
Philadelphia, PA, USA
|
| Maryland AB |
Outcomes Research (Economic, Clinical, Humanistic) Issues
DO WE NEED DISEASE-SPECIFIC REFERENCE CASES FOR ECONOMIC
EVALUATION?
Moderator: Michael Drummond PhD, Director,
University of York, York, UK
Panelists:
P. Tugwell,
University of Ottawa, Ottawa, Ontario, Canada;
Mark Sculpher MSc, PhD,
Professor, University of York, York, North Yorkshire, UK;
A. Maetzel, Amgen
(Europe) GmbH, Lucerne, Lucerne, Switzerland |
|
12:30PM–2:00PM
 |
LUNCH, EXHIBITS
& CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION I GRAND OPENING
& ISPOR 10 YEARS CELEBRATION
|
|
Exhibit Hall C |
|
|
1:00PM–2:00PM |
Symposium:
Methodological Issues in the Analysis of Health
Care Databases |
|
Salon 2 |
| Sponsored by IMS
Health |
 |
METHODOLOGICAL ISSUES IN THE ANALYSIS OF HEALTH CARE DATABASES
Presentations and discussion of issues in the analysis of health care
databases in the areas of design and patient selection as well as
statistical analyses. Specific topics like control for known and
unknown variables that may affect the outcome of interest and how to
handle missing data will be covered.
OPENING REMARKS
Moderator:
Stéphane Roze MsC, Director, Statistical Research, CORE
Center for Outcomes Research, Basel, Switzerland
ISSUES IN DESIGN OF HEALTH CARE DATABASES
Speaker:
Adrian Towse, Director, Office of Health Economics, London,
UK
Purposes of using health care databases. Types of databases that can
meet these requirements. Implications for design and patient inclusion
and exclusion. Examples of different databases that meet good design.
STATISTICAL
METHODS TO REDUCE TREATMENT SELECTION BIAS IN EPIDEMIOLOGICAL OR
OBSERVATIONAL HEALTH CARE DATA
Speaker:
Erik Spaepen, Medical Data Analyst, IMS HEALTH, Belgium
In prospective,
randomized trials, patients are allocated into treatment groups in a
randomized fashion, resulting in study groups with similar patient
characteristics. In observational data, since no randomization is
performed, there are often significant differences between
characteristics of the different treatment groups (e.g. cases &
controls). The influence of this treatment selection bias is one of
the most difficult hurdles to overcome when making inferences about
the outcome variables. This presentation discusses several techniques
to overcome this issue. Case-control matching is one of those
techniques. It is ideal in situations where a researcher wishes to
evaluate possible risk factors leading to a specific disease or
outcome. Another technique, using propensity scores, turns out to be
useful in the comparison of 2 or more treatment groups, to adjust for
possible differences in patient characteristics. The final step is
then to transfer the results of these bias correction methods into the
statistical analysis. Examples of continuous and dichotomous outcome
data will be used to illustrate the methodology.
OPEN
DISCUSSION
|
|
2:00PM-3:00PM |
CONTRIBUTED WORKSHOPS – SESSION I (7
workshops, 6 categories) |
| Delaware A |
Adherence/Compliance Issues
W1 METHODS FOR MEDICATION COMPLIANCE
STUDIES: AN OVERVIEW OF THE ISPOR
MEDICATION COMPLIANCE SIG GUIDELINES
Peterson AM1, Nau D2, Cramer JA3 for the MedComp SIG, 1University of
the Sciences in
Philadelphia/Philadelphia College of Pharmacy, Philadelphia, PA,
USA; 2University of
Michigan, Ann Arbor, MI, USA; 3Yale University, West Haven, CT, USA
|
| Virginia C |
Clinical Study Methodology Issues
W2 SELECTION BIAS AND USE OF PROPENSITY
SCORES IN OBSERVATIONAL STUDIES
Nordyke RJ, Cerner Health Insights, Beverly Hills, CA, USA
|
| Maryland C |
Cost Study Methodology Issues
W3 IMPROVING YOUR SAMPLE WITH BOOTSTRAP
METHODOLOGIES IN HEALTH ECONOMIC STUDIES: WHEN, WHY AND HOW?
Lamure M1, Dansette GY2, Castanier JC2, 1Lyon 1 University,
Villeurbanne, France; 2IMS
Health, Lyon, France
|
| Salon 2 |
Formulary Development Research Issues
W4 DESIGNING AND DEVELOPING BUDGET
IMPACT MODELS SUITED FOR GLOBAL ADAPTATION
Smith TW, Tierce JC, Cherry SB, ValueMedics Research, LLC, Falls
Church, VA, USA
Health Care Policy Development Issues
|
| Virginia AB |
W5 STANDARDIZED REPORTING FORMAT FOR
OUTCOMES RESEARCH OR ECONOMIC EVALUATION AND A SYSTEM TO MEASURE THE
STRENGTH OF EVIDENCE OF STUDIES
Wong PK1, Bakst A2, Mutnick A3, Blackburn J4, 1Good Samaritan
Hospital, Dayton, OH, USA;
2TAP Pharmaceutical Product Inc, Chicago, IL, USA; 3University of
Virginia Health System,
Charlottesville, VA, USA; 4University of Illinois at Chicago,
Chicago, IL, USA
|
| Delaware B |
QOL/PRO/Preference-based
Studies/Methodology Issues
W6 ESTIMATING MINIMALLY IMPORTANT
DIFFERENCE: IS IT REALLY MINIMAL?
Bala M1, McLeod L2, 1Centocor, Inc, Malvern, PA, USA; 2RTI Health
Solutions, Research
Triangle Park, NC, USA
|
| Maryland AB |
Risk Assessment/Risk Management Issues
W7 BALANCING RISKS AND BENEFITS OF
HEALTH CARE TREATMENTS IN THE 21ST CENTURY
Raisch DW1, Liu LZ2, Stang P3, Rahman A4, Lockett A5, Lipskiy N6 for
the Risk Management
SIG, 1VA Cooperative Studies Program, Albuquerque, NM, USA; 2Pfizer
Global Pharmaceuticals, New York, NY, USA; 3Galt Associates, Inc.
and West Chester University, Blue Bell, PA, USA; 4Shenandoah
University, Winchester, VA, USA; 5ICO, Leeds, W Yorkshire, UK;
6Surveillance Data Inc, Plymouth Meeting, PA, USA
|
|
2:00PM-4:00PM |
STUDENT MOCK INTERVIEW SESSION (pre-registration required) |
|
Wilson C |
|
|
3:00PM-315PM |
Break |
|
|
|
|
3:15PM-4:15PM |
CONTRIBUTED WORKSHOPS – SESSION II
(7 workshops, 7 categories)
|
Delaware A |
Adherence/Compliance Issues
W8 MEDICATION COMPLIANCE (ADHERENCE):
ISSUES AND DEFINITIONS CONSENSUS
WORKSHOP 2005
Wong PK1, Burrell A2, Ollendorf DA3, Cramer JA4, Fuldeore M5,
Fairchild C6 for the MedComp
SIG, 1Good Samaritan Hospital, Dayton, OH, USA; 2Aventis Pharma,
Bridgewater, NJ, USA;
3PharMetrics, Watertown, MA, USA; 4Yale University, West Haven, CT,
USA; 5Walgreens
Health Initiatives, Deerfield, IL, USA; 6Alcon Laboratories, Fort
Worth, TX, USA
|
| Salon 2 |
Clinical Study Methodology Issues
W9 PROVIDING INDIVIDUAL ESTIMATES OF
LIFE-EXPECTANCY FOR ECONOMIC ANALYSES OF CLINICAL TRIALS
Ishak KJ1, Proskorovsky I1, Caro JJ2, 1Caro Research Institute,
Dorval, QC, Canada; 2Caro Research, Concord, MA, USA
|
| Virginia AB |
Cost Study Methodology Issues
W10 ANALYSIS OF COSTS USING PATIENT
LEVEL DATA FROM RANDOMIZED DESIGNS
Doshi JA, Glick HA, Polsky D, University of Pennsylvania,
Philadelphia, PA, USA
|
Virginia C
|
Formulary
Development Research Issues
W11 INTEGRATING AND IMPLEMENTING
COST-EFFECTIVENESS ANALYSIS IN A FORMULARY MANAGEMENT SYSTEM AT A
COMPREHENSIVE CANCER CENTER: PEARLS AND PITFALLS
Arbuckle RB, King KM, Adamus AT, The University of Texas, M. D.
Anderson Cancer Center, Houston, TX, USA
|
| Maryland C |
Health Care Policy Development Issues
W12 USING HEALTH OUTCOMES TO MAXIMIZE
MARKET ACCESS
Tolley K, Ryan J, Mapi Values, Bollington, Cheshire, UK
|
| Maryland AB |
QOL/PRO/Preference-based
Studies/Methodology Issues
W13 USING CONJOINT ANALYSIS TO
UNDERSTAND PATIENT PREFERENCES IN OUTCOMES RESEARCH - A PRACTICAL
HOW TO GUIDE
Bridges JFP, Terris DD, University of Heidelberg, Heidelberg, Baden-Wuerttembu,
Germany
|
Delaware B
|
Risk Assessment/Risk Management Issues
W14 ISPOR MEMBER PERSPECTIVES: HOW DO
INDIVIDUALS PERCEIVE RISKS AND BENEFITS OF PHARMACEUTICALS IN
COMPARISON WITH OTHER NON-MEDICAL ACTIVITIES?
Raisch DW1, Lockett A2, Stang P3, Rahman A4, Liu LZ5, Lipskiy N6 for
the Risk Management
SIG, 1VA Cooperative Studies Program, Albuquerque, NM, USA; 2ICO,
Leeds, W Yorkshire, UK;
3Galt Associates, Inc and West Chester University, Blue Bell, PA,
USA; 4Shenandoah University, Winchester, VA, USA; 5Pfizer Global
Pharmaceuticals, New York, NY, USA; 6Surveillance Data Inc, Plymouth
Meeting, PA, USA |
|
4:15PM-430PM |
Break |
|
|
|
|
4:30PM-5:30PM |
ISPOR
FORUMS |
|
|
|
ISPOR PATIENT REGISTRY SIG FORUM |
4:30-5:30pm
Virginia C |
PATIENT REGISTRIES: OPPORTUNITY
AND RESPONSIBILITY
Key issues will be discussed, including the industry’s role
in sponsoring post-approval registries that capture “real world”
clinical, economic, and humanistic data and other evaluations
critical for a more accurate characterization of how drugs and
devices are utilized in actual medical practice. In addition, the
findings from the Patient Registry survey will be presented and
the Working Group Chairs will comment on issues involving
commercialization, safety surveillance, analytical methods,
technology, and global initiatives. The session will include an
open forum to solicit ISPOR member comments.
Moderator:
Jeffrey Trotter MM, President, Ovation Research Group,
Highland Park, IL
Speakers: Melva T. Covington MPH, MBA, PhD, Team Leader,
Global Health Outcomes
Eli Lilly and Company, Indianapolis, IN; Mohan Bala PhD,
Director, Outcomes Research
Centocor, Inc, Malvern, PA: Peter Malamis MBA,
Vice-President & General Manager, Post-Marketing Business Unit,
Scirex, Horsham, PA; Hugh Levaux PhD, CEO, Ninaza, San
Mateo, CA; Leanne Larson MHA, Vice President, Strategy &
Development, Ovation Research Group, Highland Park, IL
|
|
4:30–5:30 pm |
MEDICATION COMPLIANCE SPECIAL
INTEREST GROUP FORUM |
|
Maryland C |
Progress on each of the Work
Groups will be presented in an open forum (all welcome). There
will be an opportunity for discussions after the presentations.
Please attend to learn more about current activities and to join
this SIG in any capacity
|
|
4:30–4:35 pm |
Overview of the Medication
Compliance Special Interest Group
Moderator:
Joyce Cramer, BS,
Medication Compliance SIG Chair
& Associate Research Scientist, Yale University School of
Medicine, Department of Psychiatry, West Haven, CT, USA
Progress on each of the Work Groups wil be presented in an open
forum (all welcome). There will be an opportunity for discussions
after the presentations. Please attend to learn more about current
activities and to join this SIG in any capacity.
|
|
4:35–4:40 pm |
Standardizing Medication Compliance and Treatment Persistence
Definitions
Speakers:
Peter K. Wong
PhD, MBA, RPh,
Definitions Working Group
Co-Chair & Vice President, Clinical Effectiveness & PI, Good
Samaritan Hospital,
Dayton, OH, USA;
Anita Burrell, MA, MBA,
Definitions Working Group Co-Chair &
Global
Health Outcomes & Market Access Senior Director, Sanofi-Aventis,
Bridgewater, NJ, USA
|
|
4:40–4:45 pm |
Standards for Analyses Of
Medication Compliance And Treatment Persistence
Speakers:
Michael B. Nichol
PhD Analyses Standards Working Group
Chair & Department of Pharmaceutical Economics & Policy Chair,
University of Southern California, Los Angeles, CA, USA
|
|
4:45-4:50 pm |
Standards for Methods for Economic Analyses Related To Medication
Compliance and Treatment Persistence
Speaker: Rachel Elliott
PhD, For the Economics of Compliance Working Group, Clinical
Senior Lecturer & Harkness Fellow, in Health Care Policy, Harvard
University, Boston, MA, USA
|
|
4:55-5:00 pm |
Educating
Providers and Users Of Health Outcomes Data On The Medication
Compliance
Speakers:
Andrea Adamus, PhD, Education Working
Group Co-Chair & Research Specialist, Dept of Pharmaceutical Policy &
Outcomes Reserach, University of Texas M.D. Anderson Cancer Center,
Houston, TX, USA |
|
5:00–5:25 pm |
Breakout Group Discussions
|
|
5:25–5:30 pm |
Close |
|
4:30–5:30 pm |
HEALTH SCIENCE
POLICY COUNCIL FORUM |
Maryland AB
4:30–4:40 pm
|
Introduction
Jean Paul Gagnon PhD, RPh , Director, Public Policy,
Aventis Pharmaceuticals Inc, Bridgewater, NJ, USA |
|
4:40–4:47 pm |
Bridging the Health Measurement Gap:
Mission Impossible?
|
|
4:47–4:54 pm |
Where does
Outcomes Research fit into Evidence-based Health Care Decision-Making?
|
|
4:54-5:01 pm |
Continuous
Quality Improvement for Cost-effective Health Care Research and Global
Policy -Overall state of cost effectiveness science and practice.
|
|
5:01-5:08 pm |
Developing Standards for Drug Costs in Pharmacoeconomic Studies
|
|
5:08–5:15 pm |
Transferability of Economic Data:
When Does a Difference make a Difference?
|
|
5:15–5:22 pm |
Explaining CEA to health care
decision makers and their clients
|
|
5:22–5:30 pm |
Question and Answer
|
|
4:30-6:30pm |
STUDENT FORUM |
|
Virginia AB |
Moderators:
Zeba
M. Khan PhD, RPh, Head Health Economics &
Pricing Strategy, Cardiovascular and Metabolism Business
Franchise,
Novartis Pharma AG, Basel, Switzerland and Larry Humble RPh,
University of Louisiana at Monroe, School of Pharmacy, Monroe, LA
|
|
4:30-5:30pm |
Overview of the
Medicare Prescription Benefits Program
(Medicare Part D) and its
Opportunities for Health Services Research
Speaker:
Kim Caldwell RPh, Director, Division of Clinical &
Economic Performance, Medicare Drug Benefit Group, Centers for
Medicare & Medicaid Services, Baltimore, MD
|
|
5:30PM-6:30PM |
Medicare
Database Research Fundamentals
Speaker: Stephen Motsko
PharmD, PhD, Pharmacoepidemiology
Research Manager, The Degge Group, LTD, Arlington, VA
|
|
|
5:30PM–6:00PM |
HEALTH TECHNOLOGY SIG OPEN MEETING |
|
Delaware B |
Speaker:
Frank Papatheofanis MD, MPH, PhD, HTA SIG Chair, Director of the
Advanced Medical Technology Assessment & Policy Program and
Associate Professor of Radiology and Economics University of
California at San Diego
The mission, working groups, leadership and future activities of the
SIG will be presented.
Open to all meeting participants. |
|
5:30PM–6:15PM |
ISPOR ANNUAL
BUSINESS MEETING |
Delaware A |
| 5:30–
5:35 PM |
|
Call To Order: Lieven Annemans
PhD, 2004-2005 ISPOR President |
| 5:35-
5:40 PM |
|
Executive Director’s Report:
Marilyn Dix Smith PhD, ISPOR Executive Director |
| 5:40–
5:45 PM |
|
Treasurer’s Report: Lorne Basskin PharmD, ISPOR Treasurer |
| 5:45–
5:50 PM |
|
Audit Report: Laurie Burke MPH, RPh, Chair, ISPOR Audit Committee |
| 5:50–
5:55 PM |
|
VALUE IN HEALTH Editor-In-Chief
Report: Josephine Mauskopf PhD, Value in Health Editor-in-Chief |
| 5:55–
6:00 PM |
|
ISPOR CONNECTIONS
Editor-In-Chief Report: Steven E. Marx PharmD, MS |
| 6:00–
6:05 PM |
|
ISPOR Committee/Task Force
Reports |
| 6:05–
6:15 PM |
|
New Business: Lieven Annemans
PhD, 2004-2005 ISPOR President |
| |
|
|
|
6:00PM-8:00PM
|
EXHIBITORS’
OPEN HOUSE RECEPTION & CONTRIBUTED POSTER PRESENTATION -SESSION I
&
ISPOR 10th ANNIVERSARY CELEBRATION
|
| Exhibit Hall C |
|
|
10th Annual International Meeting Main Page
|
|
